7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Association of Punitive and Reporting State Policies Related to Substance Use in Pregnancy With Rates of Neonatal Abstinence Syndrome

      research-article
      , MD, MPH, MS 1 , 2 , , , PhD 3 , , MS 4 , , MD, MPH, MS 5 , 6 , 7 , 8 , 9 , , PhD 4 , , MD, PhD 9 , 10
      JAMA Network Open
      American Medical Association

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This cross-sectional study examines the association of state-level punitive or reporting policies related to substance use during pregnancy with rates of neonatal abstinence syndrome.

          Key Points

          Question

          Are state punitive or reporting policies related to substance use during pregnancy associated with rates of neonatal abstinence syndrome (NAS)?

          Finding

          In this repeated cross-sectional study of nearly 4.6 million births in 8 states, policies that criminalized substance use during pregnancy, considered it grounds for civil commitment, or considered it child abuse or neglect were associated with significantly greater rates of NAS in the first full year after enactment and more than 1 full year after enactment. Policies requiring reporting of suspected prenatal substance use were not associated with rates of NAS.

          Meaning

          Policy makers seeking to reduce NAS rates may wish to consider approaches favored by public health experts that focus on primary prevention.

          Abstract

          Importance

          Despite the rapidly changing policy environment regarding substance use during pregnancy, information is lacking on the association of state policies with neonatal abstinence syndrome (NAS).

          Objective

          To determine if punitive or reporting state policies related to substance use during pregnancy are associated with NAS rates.

          Design, Setting, and Participants

          This repeated cross-sectional study used retrospective, difference-in-difference analysis of live births in the State Inpatient Databases from 8 US states in varying years between January 1, 2003, and December 31, 2014. States without punitive or reporting policies were compared with states with policies before and after policy enactment using logistic regression models adjusted for individual and county-level factors and state and year fixed effects. Analyses were conducted from April 10, 2019, to July 30, 2019.

          Exposures

          Time since enactment of state policies related to substance use in pregnancy, county-level rurality and unemployment, and presence of specialized treatment programs for pregnant and postpartum women in a county.

          Main Outcome and Measures

          Rates of NAS.

          Results

          Among 4 567 963 live births, 23 377 neonates (0.5%) received a diagnosis of NAS. Among neonates with NAS, 3394 (14.5%) lived in counties without any treatment programs specifically for pregnant and postpartum women, 20 323 (86.9%) lived in metropolitan counties, and 8135 (34.8%) lived in counties in the highest unemployment quartile. In adjusted analyses among neonates in states with punitive policies, odds of NAS were significantly greater during the first full calendar year after enactment (adjusted odds ratio, 1.25; 95% CI, 1.06-1.46; P = .007) and more than 1 full year after enactment (adjusted odds ratio, 1.33; 95% CI, 1.17-1.51; P < .001). After regression adjustment, the annual NAS rate was 46 (95% CI, 43-48) neonates with NAS per 10 000 live births in states without punitive policies; 57 (95% CI, 48-65) neonates with NAS per 10 000 live births in states with punitive policies during the first full year after enactment; and 60 (95% CI, 56-65) neonates with NAS per 10 000 live births in states with punitive policies in effect for more than 1 full year. There was no association between reporting policies and odds of NAS.

          Conclusions and Relevance

          In this repeated cross-sectional analysis of 8 states, states with punitive policies were associated with greater odds of NAS immediately and in the longer term, but there was no association between NAS and states with reporting policies.

          Related collections

          Most cited references34

          • Record: found
          • Abstract: found
          • Article: not found

          Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009.

          Neonatal abstinence syndrome (NAS) is a postnatal drug withdrawal syndrome primarily caused by maternal opiate use. No national estimates are available for the incidence of maternal opiate use at the time of delivery or NAS. To determine the national incidence of NAS and antepartum maternal opiate use and to characterize trends in national health care expenditures associated with NAS between 2000 and 2009. A retrospective, serial, cross-sectional analysis of a nationally representative sample of newborns with NAS. The Kids' Inpatient Database (KID) was used to identify newborns with NAS by International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code. The Nationwide Inpatient Sample (NIS) was used to identify mothers using diagnosis related groups for vaginal and cesarean deliveries. Clinical conditions were identified using ICD-9-CM diagnosis codes. NAS and maternal opiate use were described as an annual frequency per 1000 hospital births. Missing hospital charges (<5% of cases) were estimated using multiple imputation. Trends in health care utilization outcomes over time were evaluated using variance-weighted regression. All hospital charges were adjusted for inflation to 2009 US dollars. Incidence of NAS and maternal opiate use, and related hospital charges. The separate years (2000, 2003, 2006, and 2009) of national discharge data included 2920 to 9674 unweighted discharges with NAS and 987 to 4563 unweighted discharges for mothers diagnosed with antepartum opiate use, within data sets including 784,191 to 1.1 million discharges for children (KID) and 816,554 to 879,910 discharges for all ages of delivering mothers (NIS). Between 2000 and 2009, the incidence of NAS among newborns increased from 1.20 (95% CI, 1.04-1.37) to 3.39 (95% CI, 3.12-3.67) per 1000 hospital births per year (P for trend < .001). Antepartum maternal opiate use also increased from 1.19 (95% CI, 1.01-1.35) to 5.63 (95% CI, 4.40-6.71) per 1000 hospital births per year (P for trend < .001). In 2009, newborns with NAS were more likely than all other hospital births to have low birthweight (19.1%; SE, 0.5%; vs 7.0%; SE, 0.2%), have respiratory complications (30.9%; SE, 0.7%; vs 8.9%; SE, 0.1%), and be covered by Medicaid (78.1%; SE, 0.8%; vs 45.5%; SE, 0.7%; all P < .001). Mean hospital charges for discharges with NAS increased from $39,400 (95% CI, $33,400-$45,400) in 2000 to $53,400 (95% CI, $49,000-$57,700) in 2009 (P for trend < .001). By 2009, 77.6% of charges for NAS were attributed to state Medicaid programs. Between 2000 and 2009, a substantial increase in the incidence of NAS and maternal opiate use in the United States was observed, as well as hospital charges related to NAS.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Opioid Use Disorder Documented at Delivery Hospitalization — United States, 1999–2014

            Opioid use by pregnant women represents a significant public health concern given the association of opioid exposure and adverse maternal and neonatal outcomes, including preterm labor, stillbirth, neonatal abstinence syndrome, and maternal mortality ( 1 , 2 ). State-level actions are critical to curbing the opioid epidemic through programs and policies to reduce use of prescription opioids and illegal opioids including heroin and illicitly manufactured fentanyl, both of which contribute to the epidemic ( 3 ). Hospital discharge data from the 1999–2014 Healthcare Cost and Utilization Project (HCUP) were analyzed to describe U.S. national and state-specific trends in opioid use disorder documented at delivery hospitalization. Nationally, the prevalence of opioid use disorder more than quadrupled during 1999–2014 (from 1.5 per 1,000 delivery hospitalizations to 6.5; p<0.05). Increasing trends over time were observed in all 28 states with available data (p<0.05). In 2014, prevalence ranged from 0.7 in the District of Columbia (DC) to 48.6 in Vermont. Continued national, state, and provider efforts to prevent, monitor, and treat opioid use disorder among reproductive-aged and pregnant women are needed. Efforts might include improved access to data in Prescription Drug Monitoring Programs, increased substance abuse screening, use of medication-assisted therapy, and substance abuse treatment referrals.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Pregnant women and substance use: fear, stigma, and barriers to care

              Background Substance use during pregnancy and motherhood is both a public health and criminal justice concern. Negative health consequences associated with substance use impact both the mother and the developing fetus, and there are ongoing attempts to criminalize substance use during pregnancy that put pregnant substance-using women at risk of detection, arrest, and punishment. This study explored the experiences of substance-using mothers as they navigated health and criminal justice consequences and accessed needed resources in the community. Methods In-depth life history interviews were conducted with 30 recently-pregnant women who had used alcohol or other drugs during their pregnancies. The three-part interview schedule included questions about past and current substance use, life history, and experiences with criminal justice authorities, child protective services, and health professionals. Results Women’s stories highlighted their strategies for managing their risk of detection by health or criminal justice authorities, including isolating themselves from others, skipping treatment appointments, or avoiding treatment altogether. Women described multiple barriers to treatment and healthcare, including a lack of suitable treatment options and difficulty finding and enrolling in treatment. Conclusion The findings suggest that policies that substance-using women find threatening discourage them from seeking comprehensive medical treatment during their pregnancies. The implications of the findings are discussed, particularly the need for further expansion of treatment programs and social services to meet the needs of substance-using women.
                Bookmark

                Author and article information

                Journal
                JAMA Netw Open
                JAMA Netw Open
                JAMA Netw Open
                JAMA Network Open
                American Medical Association
                2574-3805
                13 November 2019
                November 2019
                13 November 2019
                : 2
                : 11
                : e1914078
                Affiliations
                [1 ]RAND Corporation, Boston, Massachusetts
                [2 ]School of Medicine, Boston University, Boston, Massachusetts
                [3 ]RAND Corporation, Arlington, Virginia
                [4 ]RAND Corporation, Santa Monica, California
                [5 ]Department of Pediatrics, Vanderbilt University, Nashville, Tennessee
                [6 ]Mildred Stahlman Division of Neonatology, Vanderbilt University, Nashville, Tennessee
                [7 ]Vanderbilt Center for Child Health Policy, Nashville, Tennessee
                [8 ]Department of Health Policy, Vanderbilt University, Nashville, Tennessee
                [9 ]RAND Corporation, Pittsburgh, Pennsylvania
                [10 ]School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
                Author notes
                Article Information
                Accepted for Publication: September 6, 2019.
                Published: November 13, 2019. doi:10.1001/jamanetworkopen.2019.14078
                Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2019 Faherty LJ et al. JAMA Network Open.
                Corresponding Author: Laura J. Faherty, MD, MPH, MS, RAND Corporation, 20 Park Plaza, Ste 920, Boston, MA 02116 ( lfaherty@ 123456rand.org ).
                Author Contributions: Dr Faherty had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
                Concept and design: Faherty, Patrick, Stein.
                Acquisition, analysis, or interpretation of data: All authors.
                Drafting of the manuscript: Faherty, Kranz, Stein.
                Critical revision of the manuscript for important intellectual content: All authors.
                Statistical analysis: Faherty, Kranz, Russell-Fritch, Patrick, Cantor.
                Obtained funding: Faherty, Kranz, Stein.
                Supervision: Faherty, Patrick, Stein.
                Conflict of Interest Disclosures: None reported.
                Funding/Support: Funding for this work was provided by grants from the National Institute on Drug Abuse of the National Institutes of Health (R21DA045212 [Dr Faherty], R01DA045729 [Dr Patrick], and P50DA046351 [Dr Stein]).
                Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
                Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
                Additional Contributions: Hilary Peterson, BA (RAND Corporation), prepared this work for submission. Aaron Kofner, MA, MS, Russell Hanson, BA, BS, and Sujeong Park, MS (RAND Corporation), prepared the county-level data for analyses. They were not compensated for these contributions.
                Article
                zoi190540
                10.1001/jamanetworkopen.2019.14078
                6902764
                31722022
                40692347-c968-458a-b33b-37f20a6b2beb
                Copyright 2019 Faherty LJ et al. JAMA Network Open.

                This is an open access article distributed under the terms of the CC-BY License.

                History
                : 8 August 2019
                : 6 September 2019
                Categories
                Research
                Original Investigation
                Online Only
                Pediatrics

                Comments

                Comment on this article